Medtronic, Boston Scientific and other medtech leaders are competing to commercialize catheter technology with roots in Minnesota that’s making atrial fibrillation treatment safer.
The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.